PIERIS PHARMACEUTICALS INC (PIRS) Stock Price, Quote, News and Overview
NASDAQ:PIRS - Nasdaq - US7207952026 - Common Stock - Currency: USD
PIRS Quote, Performance and Key Statistics
13.6
-2.53 (-15.69%)
The current stock price of PIRS is 13.6 USD. In the past month the price decreased by -14.73%. In the past year, price increased by 2.97%.
PIRS Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.1 | 306.21B | ||
| AMGN | AMGEN INC | 13.98 | 148.94B | ||
| GILD | GILEAD SCIENCES INC | 22.89 | 131.52B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1685.38 | 125.65B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.77 | 63.70B | ||
| ARGX | ARGENX SE - ADR | 322.55 | 36.63B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.61B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.31B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.90B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.76B | ||
| NTRA | NATERA INC | N/A | 19.35B | ||
| BIIB | BIOGEN INC | 7.2 | 17.35B |
Related stock screener links
About PIRS
Company Profile
Pieris Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts and currently employs 46 full-time employees. The company went IPO on 2014-12-18. Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.
Company Info
PIERIS PHARMACEUTICALS INC
225 Franklin Street, 26th Floor
Boston MASSACHUSETTS 02109 US
CEO: Stephen S. Yoder
Employees: 48
Company Website: https://www.pieris.com/
Investor Relations: http://ir.pieris.com/
Phone: 18572468998
PIERIS PHARMACEUTICALS INC / PIRS FAQ
What is the stock price of PIERIS PHARMACEUTICALS INC today?
The current stock price of PIRS is 13.6 USD. The price decreased by -15.69% in the last trading session.
What is the ticker symbol for PIERIS PHARMACEUTICALS INC stock?
The exchange symbol of PIERIS PHARMACEUTICALS INC is PIRS and it is listed on the Nasdaq exchange.
On which exchange is PIRS stock listed?
PIRS stock is listed on the Nasdaq exchange.
What is PIERIS PHARMACEUTICALS INC worth?
PIERIS PHARMACEUTICALS INC (PIRS) has a market capitalization of 108.39M USD. This makes PIRS a Micro Cap stock.
How many employees does PIERIS PHARMACEUTICALS INC have?
PIERIS PHARMACEUTICALS INC (PIRS) currently has 48 employees.
What are the support and resistance levels for PIERIS PHARMACEUTICALS INC (PIRS) stock?
PIERIS PHARMACEUTICALS INC (PIRS) has a resistance level at 16.18. Check the full technical report for a detailed analysis of PIRS support and resistance levels.
Is PIERIS PHARMACEUTICALS INC (PIRS) expected to grow?
The Revenue of PIERIS PHARMACEUTICALS INC (PIRS) is expected to decline by -79.28% in the next year. Check the estimates tab for more information on the PIRS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PIERIS PHARMACEUTICALS INC (PIRS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PIRS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PIRS, evaluating the profitability, health, valuation and growth aspects
- PIERIS PHARMACEUTICALS INC (PIRS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PIERIS PHARMACEUTICALS INC (PIRS) Sales and EPS estimates to see what analysts future expectations are.
- PIERIS PHARMACEUTICALS INC (PIRS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PIERIS PHARMACEUTICALS INC (PIRS) Insider and Institutional Ownership to learn about the owners and their transactions.
- PIERIS PHARMACEUTICALS INC (PIRS) Stock Chart to make your own analysis
- PIERIS PHARMACEUTICALS INC (PIRS) Latest news and press-releases to stay up to date.
Does PIERIS PHARMACEUTICALS INC (PIRS) stock pay dividends?
PIRS does not pay a dividend.
What is the Price/Earnings (PE) ratio of PIERIS PHARMACEUTICALS INC (PIRS)?
PIERIS PHARMACEUTICALS INC (PIRS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.61).
PIRS Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PIRS. When comparing the yearly performance of all stocks, PIRS is a bad performer in the overall market: 72.72% of all stocks are doing better.
PIRS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to PIRS. While PIRS seems to be doing ok healthwise, there are quite some concerns on its profitability.
PIRS Financial Highlights
Over the last trailing twelve months PIRS reported a non-GAAP Earnings per Share(EPS) of -12.61. The EPS increased by 54.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.74% | ||
| ROE | -98.06% | ||
| Debt/Equity | 0 |
PIRS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to PIRS. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 42.86% and a revenue growth -79.28% for PIRS